J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B

Key Takeaways J&J will buy Halda for $3.05B, adding its targeted oral cancer platform and lead prostate cancer therapy.The deal brings HLD-0915, a once-daily therapy showing early anti-tumor activity in metastatic prostate J&J expects the acquisition to close in the coming months.Johnson & Johnson (JNJ) announced a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotech developing targeted oral cancer medicines, for $3.05 billion in cash.The acquisition will bring Halda’s proprietary RI ...